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Abstract
Background: Transforming growth factor-b1 (TGF-b1) is a multifunctional cytokine involved in inflammation and
pathogenesis of atherosclerosis. There is scant information on the relation between variations within the TGF-b1
gene polymorphisms and risks of ischemic cerebrovascular diseases. Therefore, this case-controlled study was
carried out to investigate the possible association of the TGF-b1 gene C-509T and T869C polymorphisms, and their
combined genotypes with the risk of atherosclerotic cerebral infarction (CI) in the Chinese population.
Results: We recruited 164 CI patients and 167 healthy control subjects who were frequency-matched for age and
gender. The frequencies of the -509TT genotype and T allele gene were significantly higher in the CI group (P =
0.007, P = 0.006). The frequencies of +869CC genotype and C allele were higher in the CI group (P = 0.002, P =
0.004). In the CI group, the individuals with -509TT genotype had a significantly higher level of plasma triglyceride
(TG) (P = 0.017). +869CC genotype correlated significantly with higher level of plasma low density lipoprotein
cholesterol (LDL-c) in the CI group (P = 0.015). With haplotype analysis, the frequency of the -509T/+869C
combined genotype was significantly higher in the CI group than in controls (P < 0.001).
Conclusions: Our study suggests that C-509T and T869C gene polymorphisms in TGF-b1 may be a critical risk
factor of genetic susceptibility to CI in the Chinese population.
Background
The etiology of atherosclerotic cerebral infarction (CI) is
complicated as genetic and environmental factors are all
involved. Epidemiological and animal studies have showed
that genetic factors determine the development of cere-
brovascular disease (CVD) [1,2]. Significant researches
have been conducted to establish the relationship between
the functional variants of a variety of genes and the risk of
stroke in different ethnic groups across the world [3].
These include the endothelial nitric oxide synthase gene
[4], angiotensin-converting enzyme gene[5], genes
associated with lipid metabolism [e.g. lipoprotein lipase,
and paraoxonase-1] [6], thrombosis and coagulation (e.g.
factor V Leiden, fibrinogen, and prothombin), Apolipopro-
tein E, 5.10, Methylenetetrahydrofolate reductase, and Pro-
tein Z gene, etc. Inflammation plays an important role in
the pathogenesis of atherosclerosis and arterial thrombosis
[7]. Variations in the genetics of the inflammatory system
may increase the risk of diseases, such as ischemic heart
disease [8]. Transforming growth factor-b1 (TGF-b1) is a
multifunctional cytokine involved in inducing cell differen-
tiation, vascularization, and migration [9]. Compelling evi-
dences showed that TGF-b1i si n v o l v e di np a t h o l o g i c
states such as inflammation processes, atherosclerosis, and
restenotic lesions [8,10,11]. However, the roles of TGF-b1
on cardiovascular and cerebrovascular diseases are contro-
versial. Numerous studies ha v ed e m o n s t r a t e dt h a tt h e
involvement of TGF-b1 in atherosclerosis plays a key role
by inhibiting inflammation and increasing atherosclerotic
* Correspondence: enxu@163.net
† Contributed equally
1Institute of Neurosciences, The Second Affiliated Hospital of Guangzhou
Medical College, Key Laboratory of Neurogenetics and Channelopathies of
Guangdong Province and the Ministry of Education of China, Guangzhou
510260, P.R. China
Full list of author information is available at the end of the article
Peng et al. Lipids in Health and Disease 2011, 10:100
http://www.lipidworld.com/content/10/1/100
© 2011 Peng et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.plaque stabilization, and hence appears to be anti-athero-
genic [12-14]. However, recent studies demonstrated that
TGF-b1 is associated with vascular stenosis and thrombo-
genesis [15,16] by promoting fibrosis and inhibiting
endothelial regeneration [17,18] and hence is a pro-athero-
genic factor.
The TGF-b1 gene is located on chromosome 19 (q13.1-
13.3). Six commonly known polymorphisms were found in
the TGF-b1 gene, including C-988A (rs1800820), G-800A
(rs1800468), C-509T (rs1800469), T869C (rs1982073;
Leu10/Pro10; T29->C), G915C (rs1800471), and C11929T
(Thr263Ile; rs1800472) [19-21]. The previous studies
attempted to determine whether naturally occurring poly-
morphisms in the TGF-b1 gene affect TGF-b1 expression
[20,22,23]. A C-to-T single nucleotide polymorphism
(SNP) at position-509 relative to the first major transcrip-
tion start site was found to be differentially related to tran-
scription factor binding to the TGF-b1 promoter,
transcriptional activity of TGF-b1, and TGF-b1p l a s m a
concentration [20,24]. The T869C SNP is located at posi-
tion 29 of the translated sequence of TGF-b1a n dg i v e s
rise to amino acid substitutions at position 10 (Leu10Pro)
in the signal peptide of TGF-b1. The T869C SNP was
reported to influence steady-state concentrations of TGF-
b1 mRNA in peripheral blood mononuclear cells and
serum levels of TGF-b1[ 2 2 , 2 5 ] .A l s o ,in vitro experiments
have reported that the Pro10Leu substitution in the signal
peptide affected significantly the secretion of the TGF-b1
protein in HeLa cells [23]. Up to now, several TGF-b1
gene mutation loci have been detected to investigate the
alternation of lipid levels in plasma and the development
of coronary artery disease (CAD) and atherosclerotic cere-
bral infarction. Of these, C-509T and T869C gene poly-
morphisms are common. The C-509T gene polymorphism
of promoter region of TGF-b1 gene is associated with the
level of plasma LDL-c [26] and myocardial infarction (MI)
in the German white population [27] and young Italian
population [28], but the corresponding study in the Dutch
[29] was negative. The T869C gene polymorphism in exon
1o ft h eT G F - b1 gene was also reported to be associated
with elevated serum lipoprotein (a) in renal transplant
recipients [30] and MI in Japanese [22] and young Italian
population [28], but the corresponding studies in other
races [29,31,32] were negative. Sie et al. [29] reported that
the C-509T and T869C gene polymorphisms were asso-
ciated with CI.
Recent studies have demonstrated the critical role of
the TGF-b1 signaling pathway in atherosclerosis [33].
Furthermore, the influence of polymorphisms of TGF-
b1 gene on inter-individual variation in atherosclerotic
vascular disease inspired us to postulate that TGF-b1C -
509T and T869C gene polymorphisms may influence
CI. Therefore, the objective of the present research was
to clarify the relationship among these two TGF-b1
gene polymorphisms, plasma lipid profile, and CI, and
to explore whether there is any combined genotype that
plays a cardinal role in the process of CI.
Methods
Subjects
The study recruited 164 CI patients (100 male and 64
female, aged 42-76 years), who were admitted to Depart-
ment of Neurology of the Second Affiliated Hospital of
Guangzhou Medical College (44 patients) and Department
of Neurology of the First Affiliated Hospital of Guangdong
Pharmaceutical College (120 patients), and 167 healthy
subjects (95 male and 72 female, aged 52-79 years) who
had no history or family history of CVDs as controls.
All subjects enrolled in our study were Chinese with
similar dietary pattern, excluding those who had gastroin-
testinal, severe hepatic, biliary, renal, thyroid diseases,
autoimmune diseases, diabetes mellitus, tumor, or malnu-
trition, and those who had accepted organ transplantation,
and one vegetarian. None of them was on any lipid-
affected drugs prior to enrollment.
All patients presented clinical characteristics of CI in
anterior circulation, confirmed by cranial computed tomo-
graphy or magnetic resonance imaging/angiography, or
both. Color Doppler carotid artery ultrasonography was
performed for all CI patients. Detailed history of patients,
physical examination, electrocardiography (ECG), pro-
longed cardiac monitoring (Holter) and transthoracic
echocardiography (TTE) were used to exclude cardioem-
bolic stroke. Also excluded were patients who had arthri-
tis, hematopathy, vascular malformation, asymptomatic
CI, hemorrhagic infarction and/or intracranial hemor-
rhage. All the experiments on the subjects were conducted
in accordance with the Declaration of Helsinki. Besides,
the study was approved by the Hospital Institutional Ethics
Committee, and written informed consent was obtained
from all study participants.
Plasma lipid measurements
Blood samples for the lipid measurements were with-
drawn from subjects after an overnight fast. Plasma
levels of triglycerides (TG), total cholesterol (TC), high
density lipoprotein (HDL-c), and low density lipoprotein
cholesterol (LDL-c) were measured by Hitachi 7600
automatic analyzer (Hitachi Instruments Corporation,
Tokyo, Japan).
DNA isolation and PCR amplification
Genomic DNA was extracted from peripheral blood leu-
kocytes by the phenol/chloroform method. The primer
sets (SBS Genetech, Beijing, China) were based on pre-
viously published information [31,34]: C-509T, forward
primer: 5’-CAG ACT CTA GAG ACT GTC AG-3’ and
reverse primer: 5’-GTC ACC AGA GAA AGA GGA C-3’;
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TTC GC-3’ and reverse primer: 5’-AGT AGC CAC AGC
AGC GGT AGC AGC TGC-3’. The PCR amplification of
C-509T was performed in a total volume of 30 μl mixture
containing: 3 μl (150 ng) genomic DNA, 3 μl 10× buffer
solution, 0.5 μl2 . 5UTaqDNA polymerase (Shenergy
Biocolor Bioscience & Technology Company, Shanghai,
China), 1 μl (20 pmol) of each primer, and 3 μl( 2 0 0μmol/
l) of each deoxynucleotide triphosphate. The PCR condi-
tions were as follows: initial denaturations at 93°C for
5 min were followed by 30 cycles of denaturations at 93°C
for 45 s, annealing at 54°C for 45 s, and extension at 72°C
for 45 s, with final extension at 72°C for 7 min. Genomic
DNA 2 μl (100 ng) of T869C was used for a 50 μlP C R
reaction containing 10 μl 5×buffer solution, 1 μl( 3U / μl)
TaqDNA polymerase (Shenergy Biocolor Bioscience &
Technology Company), 1 μl (10 pmol) of each primer, and
1 μl (10 mM) of each deoxynucleotide triphosphate. The
PCR conditions were as follows: initial denaturations at
93°C for 5 min were followed by 40 cycles of denaturations
at 93°C for 30 s, annealing at 55°C for 45 s, and extension
at 72°C for 45 s, with final extension at 72°C for 7 min.
TGF-b1 gene polymorphism analysis
Digestion of PCR product was performed by addition of
1 μl respective restriction enzyme (C-509T: Eco81I;
T869C: Pst Ι (TAKARA Biotechnology Co., Ltd., Dalian,
China)) to 10 μlo fP C Rp r o d u c t si n2μl1 0×b u f f e r
solution, centrifuged for 2 min at the speed of 5000
rounds/min and bathed in aqueous environment at 37°C
overnight. The resulting fragments were resolved by
electrophoresis (80 V, 60 min) on 2.5% agarose gel and
visualized under UV light.
Direct sequencing of DNA fragment
Direct sequencing of double-stranded DNA fragment
was performed by using Beckman DNA sequencer
(Beckman Coulter, Inc, Fullerton, CA, USA).
Statistical analysis
Measurement data were summarized as mean ± standard
deviation (S.D.) and compared with two-sample t-test.
Enumeration count data were summarized as number
(%) and compared with chi-square test (x
2-test). To
assess the Hardy-Weinberg equilibrium for the C-509T
and T869C genotype distribution, x
2 analysis was per-
formed. The odds ratios (ORs) and 95% CI were used to
assess the strength of the relationship in the genotype
and allele distribution of polymorphisms C-509T and
T869C between the CI group and controls. Haplotype
frequencies were estimated in the C-509T and T869C
polymorphisms, and the ORs and 95% CI were also used
to estimate the haplotype association risk between the CI
group and controls. All tests were two-side and a P value
< 0.05 was considered statistically significant. Statistical
analyses were performed with the Statistical Package for
Social Sciences for Windows, version 11.5 (SPSS, Inc,
Chicago, IL, USA).
Results
Clinical characteristics of the 331 participants (164 CI
patients and 167 control subjects) are presented in
Table 1. The risk factors examined (e.g. CAD, hyperten-
sion, and smoker) were significantly more common in
the CI group than in controls. Systolic blood pressure
(SBP), diastolic blood pressure (DBP), and plasma level
of TG tended to be higher, while HDL-C was lower in
CI patients than in controls at admission.
All genotype and allele proportions were in Hardy-
Weinberg equilibrium in both controls and CI group.
The genotype distribution and the allele frequency for
C-509T and T869C gene polymorphisms are summar-
ized in Table 2. A preliminary case-control analysis of
the population revealed significant differences in the
allele and genotype frequency of both C-509T and
T869C site polymorphisms. The frequency of T allele of
C-509T was significantly higher in the CI group than in
controls (P < 0.006). The distribution of C-509T gene
polymorphism demonstrated that CI patients had higher
TT frequency compared with controls (P < 0.007). The
frequency of C allele of T869C was significantly higher
in the CI group than in controls (P < 0.004). The distri-
bution of T869C gene polymorphism demonstrated that
CI patients had higher CC frequency compared with
controls (P < 0.002).
Table 1 Characteristic of Controls and CI Patients
Characteristic Controls CI group P value
n 167 164
Age, years 63.68 ± 6.65 64.87 ± 6.16 0.094
Female, % 72(43.1) 64(39.0) 0.450
BMI, Kg/m
2 22.60 ± 1.90 22.92 ± 1.89 0.118
SBP, mmHg 127.62 ± 12.33 148.08 ± 23.71 <0.001
DBP, mmHg 75.12 ± 6.20 85.63 ± 13.56 <0.001
CAD, % 5(3.0) 15(9.1) 0.019
TG, mmol/L 1.28 ± 0.41 1.64 ± 0.61 <0.001
TC, mmol/L 5.17 ± 0.86 5.13 ± 1.12 0.670
HDL-c, mmol/L 1.38 ± 0.35 1.26 ± 0.34 0.002
LDL-c, mmol/L 3.08 ± 0.73 3.14 ± 0.97 0.493
Hypertension, % 14(8.4) 93(56.7) <0.001
Smoker, % 45(26.9) 67(40.9) 0.008
Drinker, % 44(26.3) 36(22.0) 0.263
Data are presented as means ± S.D. or n (%). Student’s t test and c2 test were
used to compare the values of controls and CI patients. BMI, body mass index;
SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary
artery disease; TG, triglyceride; TC, total cholesterol; HDL-c, high density
lipoprotein cholesterol; LDL-c, low density lipoprotein cholesterol.
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vation of TGF-b1 [35] and that this could be an impor-
tant mechanism in the initiation and progression of
atherosclerosis, a possible interaction was tested
between lipid levels of plasma and the TGF-b1 C-509T
and T869C gene polymorphisms on the risk of CI. The
C-509T and T869C mutations did not correlate signifi-
cantly with levels of plasma TG, TC, HDL-c, and LDL-c
in controls (data not shown). In the CI group, the indi-
viduals with -509TT genotype had a significantly higher
level of plasma TG. Compared with 869CT and 869TT
mutation, 869CC genotype correlated with a signifi-
cantly higher level of plasma LDL-c. The relationships
between genotypes and levels of plasma lipids in the CI
group are shown in Table 3.
To address the possibility of combined effects of the
TGF-b1 single nucleotide polymorphisms (SNPs), the
possible associations between SNP-based haplotypes and
CI were examined. The distribution of combined geno-
type is presented in Table 4. The frequency of T/C
(-509T and 869C) combined genotypes was higher in the
C Ig r o u pt h a ni nc o n t r o l s( P < 0.001). The frequency of
C/T (-509C and 869T) combined genotype was lower in
the CI group than in control subjects (P = 0.010).
Figure 1 and Figure 2 show direct sequencing of geno-
mic DNA in the vicinity of C-509T and T869C loci of
TGF-b1 gene.
Discussion
The present study was the first time to evaluate the rela-
tionships between SNPs at the TGF-b1 loci and CI and
lipid levels of plasma in the Chinese population. The
major findings of our study were as follows: (1) the
-509T and the 869C allele are more frequent in CI
patients than in controls. (2) In the CI group, the indivi-
duals with -509TT genotype had a significantly higher
level of plasma TG, and +869CC genotype correlated
with significantly higher level of plasma LDL-c in the CI
group. (3) The frequency of the -509T/+869C combined
genotype was significantly higher in the CI group than
in controls.
The C-509T polymorphism of the TGF-b1g e n ei s
located in the promoter region which is relative to the
first major transcription start site and was found to be
Table 2 Genotype Distributions and allele Frequencies of the C-509T and T 869C
Genotype, n (%) Allele Frequency
-509C/T TT CT CC T Allele (%)
Controls (n = 167) 59(35.3) 79(47.3) 29(17.4) 59.0
CI Group (n = 164) 82(50.0) 63(38.4) 19(11.6) 69.2
OR 1.83 0.70 0.63 1.56
95% CI 1.18-2.85 0.45-1.08 0.33-1.16 1.14-2.15
P value 0.007 0.135 0.102 0.006
869T/C TT TC CC C Allele (%)
Controls (n = 167) 46 (27.5) 86(51.5) 35(21.0) 46.7
CI Group (n = 164) 34(20.7) 70(42.7) 60(36.6) 57.9
OR 0.69 0.70 2.18 1.57
95% CI 0.41-1.14 0.46-1.08 1.33-3.55 1.16-2.14
P value 0.148 0.108 0.002 0.004
Table 3 Plasma Concentrations of TG, TC, HDL-c, and LDL-c in Various Genotypes of the C-509T and T 869C in CI
Group
Genotype TG(mmol/L) TC(mmol/L) HDL-c(mmol/L) LDL-c(mmol/L)
-509C/T
TT 1.79 ± 0.56 5.28 ± 1.17 1.27 ± 0.35 3.26 ± 0.95
CT 1.53 ± 0.67 4.91 ± 0.94 1.22 ± 0.31 3.09 ± 0.80
CC 1.48 ± 0.43 5.17 ± 1.41 1.34 ± 0.42 3.11 ± 1.20
P value 0.017 0.133 0.378 0.513
869T/C
TT 1.58 ± 0.68 4.92 ± 1.35 1.28 ± 0.36 2.94 ± 0.95
TC 1.61 ± 0.66 4.98 ± 1.00 1.26 ± 0.34 3.01 ± 0.86
CC 1.57 ± 0.54 5.33 ± 1.19 1.16 ± 0.24 3.43 ± 0.99
P value 0.953 0.134 0.100 0.015
Values are mean ± S.D.
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b1 plasma concentration [20]. It has been reported that
the homozygote for C in the C-509T allele of TGF-b1i s
associated with higher mRNA expression [25] and also
with higher serum concentration of TGF-b1 [22]. In the
study of Oda et al [36], it was found that the T-allele at
C-509T of TGF-b1 is a risk factor for atherogenesis of
the intracranial arteries in the Japanese elderly. Sie’s [29]
study showed that subjects with the -509CT genotype
and T-allele had a significantly increased risk of
ischemic stroke and overall stroke, including ischemic
stroke, hemorrhagic stroke and unspecified stroke. Simi-
lar to Sie’s [29] study, the frequency of the T allele in
CI patients was significantly higher than that in control
subjects, and the subjects in CI group had higher TT
frequency compared with controls in this study.
The T869C polymorphism is located in the signal pep-
tide sequence; this sequence is involved in the export of
synthesized proteins across membranes of the endoplas-
mic reticulum. Signal peptides exhibit a unity of function
despite having highly diverse sequences; however, they all
comprise three regions: a positively charged N-terminal
region, a central hydrophobic core, and a polar C-terminal
region. The T869C polymorphism is located in the hydro-
phobic core. Different classes of signal sequence mutations
changing one amino acid to another and affecting export
efficiency have been described [37], and the importance of
a change in charge in the hydrophobic core has been
stressed. The T869C polymorphism was reported to influ-
ence steady-state concentrations of TGF-b1m R N Ai n
peripheral blood mononuclear cells and serum levels of
TGF-b1 [22,25]. For the T869C polymorphism, the asso-
ciation between the polymorphism and risk of stroke in
the overall stroke group was found to be somewhat stron-
ger than in the ischemic stroke group in the study of Sie
et al [29]. However, in our study, a significantly higher CC
frequency in the CI group was found compared with con-
trols. Different genetic backgrounds between whites and
Chinese may explain, at least in part, the disparate findings
of the studies. Heterogeneities in the prevalence of con-
ventional risk factors for CI, including CAD, arterial
hypertension, hypercholesterolemia, and cigarette smoking
may have also contributed to the divergent results between
the study populations.
To date, the relationship between TGF-b1a n dl i p i d
metabolism was not completely understood. Previously,
TGF-b has been demonstrated to influence the expres-
sion of lipoproteins and regulate cholesterol metabolic
processes [38]. Also, TGF-b1 inhibits LPL mRNA expres-
sion, protein levels and enzymatic activity [39], and
hence may influence the plasma levels of lipid. On the
other hand, the study of Chen et al [35] found that
Table 4 Combined Genotype Distributions of the C-509T and T 869C in Controls and CI Group
Combined Genotype, n (%)
-509C/T/869T/C -509T/869T -509T/869C -509 C/869T -509 C/869C
Controls (n = 167) 15(9.0) 20(12.0) 125(74.8) 7(4.2)
CI group (n = 164) 10(6.1) 50(30.5) 101(61.6) 3(1.8)
OR 0.66 3.22 0.54 0.43
95% CI 0.29-1.519 1.82-5.72 0.34-0.86 0.11-1.68
P Value 0.321 <0.001 0.010 0.209
Figure 1 Direct sequencing of genomic DNA in the vicinity of -509C/T polymorphism of TGF-b1g e n e . Representative results implicate:
heterozygous subject (A); subject homozygous for C (B); subject homozygous for T (C)
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suppresses TGF-b responsiveness in vascular cells. More-
over, cholesterol-lowering agents and cholesterol-deplet-
ing agents enhance TGF-b responsiveness. However, to
our knowledge, only a few studies have been published
on the association of the TGF-b1 polymorphisms and
lipid levels of plasma. Nordström et al indicated in their
study that the absence of the C allele of C-509T was
associated with an increased level of serum LDL-c in the
adolescent females [26]. Whereas, in our study, we
observed that the plasma levels of TG were higher in
patients with the -509TT genotype than in subjects with
the CC or TC genotype in the CI group. Besides, we
found that the plasma levels of LDL-c were higher in CI
patients with the 869CC genotype than in subjects with
the TT or TC genotype. Taking together the positive
effects of the TGF-b1 C-509T and T869C gene poly-
morphisms on the CI, the present study is the first to
suggest that lipid levels of plasma and CI in the Chinese
population are related to polymorphism of the same
gene. These resultss u g g e s tt h a tT G F - b1 gene poly-
morphisms effect on the CI, which may partly be attribu-
ted to the regulation of lipid levels of plasma.
A high degree of linkage disequilibrium was observed
between pairs of the C-509T and T869C SNPs in white
populations [31]. In these regard, further haplotype analy-
sis of the two polymorphisms was conducted, which is
more useful for the identification of predisposing genes of
complicated diseases [40]. Our results demonstrated that
mutant haplotypes TC (-509T and +869C) were associated
with a higher risk for developing CI. The risk of CI occur-
ring in subjects carrying this haplotype was 3.22-fold
higher (P < 0.001) in comparison with those without the
TC (-509T and +869C) haplotype. This finding implies
that carrying the TC (-509T and +869C) haplotype is a
risk factor independently modifying individual susceptibil-
ity to the development of CI in the Chinese population.
Common complex human diseases, such as stroke, are
thought to be under the control of many genes that contri-
bute modest individual effects, and TGF-b1 may act in
concert with or independently from other stroke suscept-
ibility loci.
Conclusion
Our study suggests that the -509T and the 869C allele is
more frequent in CI patients than in controls. A signifi-
cant association was found between the C-509T and
T869C gene polymorphisms and risk of CI. The data
also provides strong evidence of an association between
polymorphisms in the TGF-b1 gene with lipid levels.
Moreover, -509T/+869C combined genotype mutation
of the TGF-b1 gene are relevant to CI. The C-509T and
T869C polymorphisms are the risk factors for CI, indi-
cating that the TGF-b1 polymorphism may remain a
useful genetic marker for predicting CI risk in the Chi-
nese. These results warrant further studies, with larger
numbers, to consolidate these findings, to investigate
the functional effects of these polymorphisms and to
study the underlying pathophysiological mechanism.
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